Our results demonstrated that the NPs effectively knocked down SEC14L3 expression in ccRCC and further inhibited the growth of subcutaneous tumors in mice when combined with sunitinib treatment. The gene discussed is SEC14L3; the disease is nonpapillary renal cell carcinoma.